Bicycle Therapeutics Limited BCYC 深 滬
已收盤 09-18 16:00:00 美东时间
24.36
-0.050
-0.20%
華盛通- 最 高26.095
- 今 開24.25
- 成交量 53.09万股
- 最 低 24.22
- 昨 收 24.41
- 總市值 10.37亿
- 52周最高 28.20
- 市盈率 靜 --
- 換手率 1.25%
- 52周最低 12.54
- 委 比 -9.72%
- 總股本 4258.62万
- 歷史最高 62.075
- 量 比 0.87
- 振 幅 7.68%
- 歷史最低 6.24
- 每 手 1
- 風險率 3.45%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股牛股 | 多只医药股狂飙！生物制药公司SMMT飙升56%，TVTX大涨17%
多只医药股狂飙！生物制药公司SMMT飙升56%，年内累涨633%，公司肺癌新药临床试验结果优异；TVTX大涨17%，公司的肾病药物获得FDA完全批准>>
09-10 16:11
Bicycle Therapeutics: Outpacing Competitors with Promising Drug Pipeline – A Buy Rating Justified
Ami Fadia, an analyst from Needham, maintained the Buy rating on Bicycle Therap...
09-09 23:45
Cantor Fitzgerald Reiterates Overweight on Bicycle Therapeutics
Cantor Fitzgerald analyst Li Watsek reiterates Bicycle Therapeutics (NASDAQ:BCYC) with a Overweight.
09-09 20:55
Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone
RBC Capital initiates coverage on Bicycle Therapeutics, highlighting Zelenectide's potential in oncology with improved safety over competitors. The analyst projects ~$2 billion in peak sales by 2033 and sees opportunities beyond metastatic urothelial cancer.
09-07 01:37
XDC厮杀摁下快进键
ADC药物作为现在最主流的偶联疗法，正在肿瘤治疗中呈现烈火烹油之势。但市场代有新药出，ADC也终将会被新的偶联疗法迭代。目前来看，这个迭代趋势正在显著加快。 多...
09-02 19:26
B. Riley Securities Downgrades Bicycle Therapeutics to Neutral, Lowers Price Target to $28
B. Riley Securities analyst Kalpit Patel downgrades Bicycle Therapeutics (NASDAQ:BCYC) from Buy to Neutral and lowers the price target from $33 to $28.
08-07 17:55
Bicycle Therapeutics: Hold Rating Amid Clinical and Competitive Challenges
Bicycle Therapeutics (BCYC – Research Report), the Healthcare sector company, w...
08-07 16:56
Bicycle Therapeutics (BCYC) Gets a Buy from TD Cowen
In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating...
08-06 22:11
华尔街到陆家嘴精选｜特斯拉连涨，储能产业链爆发在即？中东能源巨头竞购，天然气火了？
①受Alphabet首次派息推动 美股二季度净股息增长160.5亿美元 标普道琼斯指数的数据显示，二季度美国国内普通股净股息变化增加了160.5亿美元，而前一季...
07-05 09:59
美股生物制药并购潮掀起 谁将成为下一个潜在目标？
富国银行发布了其年度生物制药行业潜在并购清单，将减肥药开发商Viking Therapeutics(VKTX.US)、基因编辑公司CRISPR Therape...
05-27 11:21
